Insmed to Present at the Leerink Swann Global Healthcare Conference

Insmed to Present at the Leerink Swann Global Healthcare Conference 
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 02/04/14 --   Insmed
Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on
developing an inhaled anti-infective to treat patients battling
serious lung diseases in orphan indications that are often
life-threatening, today announced that members of the Company's
executive management team will be presenting at the Leerink Swann
Global Healthcare Conference taking place February 12-13, 2014 at the
Waldorf Astoria Hotel in New York City. 
Will Lewis, President and CEO, will present a corporate overview on
February 12th at 8:50 a.m. Eastern time. Mr. Lewis' presentation will
be webcast live on the internet and can be accessed by visiting the
Investor Relations section of the Company's website at
www.insmed.com. A replay of the webcast will be archived on t
he
Insmed website for 90 days following the presentation. 
About Insmed 
Insmed Incorporated is a biopharmaceutical company dedicated to
improving the lives of patients battling serious lung diseases.
Insmed is focused on the development and commercialization of
ARIKACE(R), or liposomal amikacin for inhalation, for at least two
identified orphan patient populations: patients with non-tuberculous
mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients
with Pseudomonas aeruginosa lung infections. For more information,
please visit http://www.insmed.com. 
Forward-looking Statements
 This release contains forward-looking
statements. Words, and variations of words, such as "intend,"
"expect," "will," "anticipate," "believe," "continue," "propose" and
similar expressions are intended to identify forward-looking
statements. Investors are cautioned that such statements in this
release, including statements relating to the status, results and
timing of clinical trials and clinical data, the anticipated benefits
of Insmed's products, the anticipated timing of regulatory
submissions, and the ability to obtain required regulatory approvals,
bring products to market and successfully commercialize products
constitute forward-looking statements that involve risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. Such risks and
uncertainties include, without limitation, failure or delay of
European, Canadian, U.S. Food and Drug Administration and other
regulatory reviews and approvals, competitive developments affecting
the Company's product candidates, delays in product development or
clinical trials or other studies, patent disputes and other
intellectual property developments relating to the Company's product
candidates, unexpected regulatory actions, delays or requests, the
failure of clinical trials or other studies or results of clinical
trials or other studies that do not meet expectations, the fact that
subsequent analyses of clinical trial or study data may lead to
different (including less favorable) interpretations of trial or
study results or may identify important implications of a trial or
study that are not reflected in Company's prior disclosures, and the
fact that trial or study results or subsequent analyses may be
subject to differing interpretations by regulatory agencies, the
inability to successfully develop the Company's product candidates or
receive necessary regulatory approvals, inability to make product
candidates commercially successful, changes in anticipated expenses,
changes in the Company's financing requirements or ability raise
additional capital, and other risks and challenges detailed in the
Company's filings with the U.S. Securities and Exchange Commission,
including its Annual Report on Form 10-K for the year ended December
31, 2012. Investors are cautioned not to place undue reliance on any
forward-looking statements that speak only as of the date of this
news release. The Company undertakes no obligation to update these
forward-looking statements to reflect events or circumstances or
changes in its expectations. 
Contacts:
LHA
Anne Marie Fields
Senior Vice President
212-838-3777
afields@lhai.com 
Bruce Voss
Managing Director
310-691-7100
bvoss@lhai.com 
 
 
Press spacebar to pause and continue. Press esc to stop.